This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kiewe, P. Articles by Untch, M. Search for Related Content PubMed PubMed Citation Articles by Kiewe, P. Articles by Untch, M.

Phase I Trial of the Trifunctional Anti-HER2 x Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Authors' Affiliations: ¹ Department of Haematology, Oncology, and Transfusion Medicine, Charité Campus Benjamin Franklin, Berlin; ² Department of Gynaecology-Breast Center, Helios Klinikum Berlin-Buch, Berlin; ³ Department of Gynaecology, Universitäts-Frauenklinik, Heidelberg; ⁴ Department of Gynecology, Klinikum der Ludwig-Maximilians-Universität München-Großhadern; ⁵ Department of Obstetrics and Gynecology, Klinikum der Ludwig-Maximilians-Universität München-Innenstadt; ⁶ TRION Pharma, Munich; and ⁷ TRION Research, Martinsried, Germany

Requests for reprints: Philipp Kiewe, Department of Haematology, Oncology, and Transfusion Medicine, Charité Campus Benjamin Franklin D-12200, Berlin, Germany. Phone: 49-30-8445-2337; Fax: 49-30-8445-4468; E-mail: philipp.kiewe{at}charite.de.

Purpose: Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with selective binding to activatory Fc type I/III receptors, resulting in the formation of a tri-cell complex between tumor cells, T cells, and accessory cells. Patients with metastatic breast cancer were enrolled into a multicenter phase I dose-escalating trial.

Experimental Design: Three ascending doses of ertumaxomab (10-200 µg) were administered i.v. on day 1, 7 ± 1, and 13 ± 1. Safety and tolerability were the primary objectives. Secondary objectives were antitumor activity and different immunologic variables.

Results: Fifteen out of 17 enrolled patients completed the study. One hundred micrograms was identified as the maximal tolerable single dose. Most drug-related adverse events were mild and transient including fever (94%), rigors (47%), headache (35%), nausea (29%), vomiting (29%). Grades 3 and 4 (Common Toxicity Criteria) were lymphocytopenia (76%) and elevation of liver enzymes (47%). One patient (200 µg dose) developed severe hypotension and respiratory distress syndrome, another patient (150 µg dose) developed a systemic inflammatory response syndrome and acute renal failure. Aggravation of congestive heart failure was seen in one patient with preexisting ventricular dysfunction after administration of the third dose (200 µg). All adverse events were fully reversible. Antitumor response was seen in 5 out of 15 evaluable patients (one with a complete response, two with partial responses, two with stable disease) at dose levels of 100 µg. Measurements of cytokines (interleukin-6, interleukin-2, tumor necrosis factor-, and IFN-) suggest a strong T helper cell type 1–associated immune response. The induction of human anti-mouse/anti-rat antibodies was detected in 5 out of 16 (31%) patients.

Discussion: Treatment with triple infusions of ertumaxomab yields a strong immunologic response. Doses up to 100 µg can be safely infused with close monitoring of patients. The observed clinical responses are encouraging and indicate antitumor efficacy.

This article has been cited by other articles:

				M. Jager, A. Schoberth, P. Ruf, J. Hess, and H. Lindhofer The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2 Cancer Res., May 15, 2009; 69(10): 4270 - 4276. [Abstract] [Full Text] [PDF]

				C.-H. Lee, Y.-H. Chiang, S.-E. Chang, C.-L. Chong, B.-M. Cheng, and S. R. Roffler Tumor-Localized Ligation of CD3 and CD28 with Systemic Regulatory T-Cell Depletion Induces Potent Innate and Adaptive Antitumor Responses Clin. Cancer Res., April 15, 2009; 15(8): 2756 - 2766. [Abstract] [Full Text] [PDF]

				J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]

				A. Burges, P. Wimberger, C. Kumper, V. Gorbounova, H. Sommer, B. Schmalfeldt, J. Pfisterer, M. Lichinitser, A. Makhson, V. Moiseyenko, et al. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I/II Study Clin. Cancer Res., July 1, 2007; 13(13): 3899 - 3905. [Abstract] [Full Text] [PDF]